Abstract:Background: Protein arginine methyltransferase 5 (PRMT5) is a type II arginine methyltransferase that symmetrically di-methylates arginine residues on both histone and non-histone protein substrates. Accumulating evidence suggests that PRMT5 exerts its oncogenic properties in a wide spectrum of human malignancies. However, the underlying mechanisms by which PRMT5 contributes to the progression of colorectal cancer (CRC) remain to be defined.Methods: Western blot and real-time PCR were used to analyze the expression of CDKN2B. Co-immunoprecipitation (Co-IP), immunofluorescence and GST pulldown assays were employed to investigate the interaction between PRMT5 and EZH2. Luciferase reporter and chromatin immunoprecipitation (ChIP) assays were performed to validate CDKN2B as a direct target of PRMT5/EZH2. DNA methylation status at the CpG islands of promoter region of CDKN2B gene was analyzed by bisulfite sequencing. The effect of PRMT5/EZH2 on malignant phenotypes was examined through in vitro and in vivo assays. PRMT5 and EZH2 protein expression levels in CRC tissues were analyzed by immunohistochemistry (IHC) staining.Results: We observed that PRMT5-deficient CRC cells exhibit proliferation defects in vitro. PRMT5 was identified as a major transcriptional repressor of CDKN2B (p15INK4b) for determining CRC progression. Mechanistically, PRMT5-mediated histone marks H4R3me2s and H3R8me2s were predominantly deposited at the promoter region of CDKN2B gene in CRC cells. Knockdown of PRMT5 in CRC cells decreased the accumulation of H4R3me2s and H3R8me2s marks and reduced the CpG methylation level of CDKN2B promoter, then re-activated CDKN2B expression. Strikingly, silencing of CDKN2B partially abrogated the proliferation defects caused by PRMT5 depletion in vitro and in vivo. Furthermore, we proved that PRMT5 interacted with Enhancer of zeste homolog 2 (EZH2), leading to enhanced EZH2 binding and H3K27me3 deposition together with decreased transcriptional output of CDKN2B gene. Importantly, we found that the combined interventions exerted a synergistic inhibitory effect of combined treatment with PRMT5i (GSK591) and EZH2i (GSK126) on the growth of CRC cells/xenografts in vitro and in vivo. Moreover, PRMT5 and EZH2 were found to be significantly elevated and associated with poor prognosis in CRC patients.Conclusion: PRMT5 functionally associates with EZH2 to promote CRC progression through epigenetically repressing CDKN2B expression. Thus, our findings raise the possibility that combinational intervention of PRMT5 and EZH2 may be a promising strategy for CRC therapy.

PRMT1-mediated EZH2 methylation promotes breast cancer cell proliferation and tumorigenesis

Methylation of EZH2 by PRMT1 regulates its stability and promotes breast cancer metastasis

PRMT1-mediated H4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling

Decreased Expression of EZH2 Reactivates RASSF2A by Reversal of Promoter Methylation in Breast Cancer Cells

Arginine Methyltransferase PRMT1 Regulates p53 Activity in Breast Cancer

PRMT1-mediated methylation of ME2 promotes hepatocellular carcinoma growth by inhibiting ubiquitination

Targeting PRMT1-mediated SRSF1 methylation to suppress oncogenic exon inclusion events and breast tumorigenesis

PRMT1 in human neoplasm: cancer biology and potential therapeutic target

PRMT2 promotes RCC tumorigenesis and metastasis via enhancing WNT5A transcriptional expression

PRMT5 functionally associates with EZH2 to promote colorectal cancer progression through epigenetically repressing CDKN2B expression

Arginine methylation of DDX3 by PRMT1 mediates mitochondrial homeostasis to promote breast cancer metastasis

Protein Arginine Methyltransferase 1 Promotes Epithelial-Mesenchymal Transition Via TGF-β1/Smad Pathway in Hepatic Carcinoma Cells

The EZH2–PHACTR2–AS1–Ribosome Axis Induces Genomic Instability and Promotes Growth and Metastasis in Breast Cancer

Methylation of BRD4 by PRMT1 regulates BRD4 phosphorylation and promotes ovarian cancer invasion

Automethylation of Protein Arginine Methyltransferase 7 and Its Impact on Breast Cancer Progression

EZH2 overexpression dampens tumor-suppressive signals via an EGR1 silencer to drive breast tumorigenesis

PRMT3‐Mediated Arginine Methylation of METTL14 Promotes Malignant Progression and Treatment Resistance in Endometrial Carcinoma

Arginine and lysine methylation of MRPS23 promotes breast cancer metastasis through regulating OXPHOS

EZH2-Mediated Microrna-375 Upregulation Promotes Progression of Breast Cancer Via the Inhibition of FOXO1 and the P53 Signaling Pathway.

MeCP2 Facilitates Breast Cancer Growth Via Promoting Ubiquitination-Mediated P53 Degradation by Inhibiting RPL5/RPL11 Transcription

PRMT1 Regulates the Tumour-Initiating Properties of Esophageal Squamous Cell Carcinoma Through Histone H4 Arginine Methylation Coupled with Transcriptional Activation